格林生物
(301688)
| 流通市值：8.69亿 | | | 总市值：44.61亿 |
| 流通股本：2598.50万 | | | 总股本：1.33亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 875,693,674.17 | 608,180,576.57 | 318,053,000 | 1,074,915,761.58 |
| 营业收入 | 875,693,674.17 | 608,180,576.57 | - | 1,074,915,761.58 |
| 二、营业总成本 | 714,121,494.38 | 489,935,155.05 | - | 865,197,564.17 |
| 营业成本 | 600,280,154.13 | 413,697,530.84 | - | 733,513,886 |
| 税金及附加 | 7,606,201.89 | 5,613,711.96 | - | 8,422,658.05 |
| 销售费用 | 6,772,447.2 | 4,498,356.32 | - | 8,413,995.33 |
| 管理费用 | 38,412,830.16 | 25,032,100.79 | - | 51,793,659.99 |
| 研发费用 | 28,322,952.88 | 18,237,513.69 | - | 37,259,255.34 |
| 财务费用 | 32,726,908.12 | 22,855,941.45 | - | 25,794,109.46 |
| 其中:利息费用 | 18,455,753.29 | 12,205,891.9 | - | 26,582,755.7 |
| 其中:利息收入 | 797,515.19 | 381,220.09 | - | 107,861.95 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -381,630 | -381,630 | - | - |
| 资产处置收益 | -637.9 | -452.05 | - | -649,237.27 |
| 资产减值损失(新) | -674,751.12 | -2,041,216.1 | - | -3,744,624.64 |
| 信用减值损失(新) | -2,665,574.39 | -3,551,674.45 | - | -1,470,092.28 |
| 其他收益 | 2,522,615.28 | 2,352,682.38 | - | 2,654,671.91 |
| 营业利润平衡项目 | 0 | 0 | - | 0 |
| 四、营业利润 | 160,372,201.66 | 114,623,131.3 | 59,795,900 | 206,508,915.13 |
| 加:营业外收入 | 13,640.02 | 12,440 | - | 28,458.2 |
| 减:营业外支出 | 55,299.56 | 55,299.56 | - | 253,689.12 |
| 利润总额平衡项目 | 0 | 0 | - | 0 |
| 五、利润总额 | 160,330,542.12 | 114,580,271.74 | 59,742,300 | 206,283,684.21 |
| 减:所得税费用 | 21,516,809.57 | 16,059,045.96 | - | 27,324,613.08 |
| 六、净利润 | 138,813,732.55 | 98,521,225.78 | - | 178,959,071.13 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 138,813,732.55 | 98,521,225.78 | - | 178,959,071.13 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 138,813,732.55 | 98,521,225.78 | 50,086,900 | 178,959,071.13 |
| 扣除非经常损益后的净利润 | 136,991,347.52 | 96,844,205.92 | 49,792,700 | 177,339,184.72 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.34 | 0.99 | - | 1.79 |
| (二)稀释每股收益 | 1.34 | 0.99 | - | 1.79 |
| 八、其他综合收益 | -37,743.95 | 325,758.17 | - | 206,475.95 |
| 归属于母公司股东的其他综合收益 | -37,743.95 | 325,758.17 | - | 206,475.95 |
| 九、综合收益总额 | 138,775,988.6 | 98,846,983.95 | - | 179,165,547.08 |
| 归属于母公司股东的综合收益总额 | 138,775,988.6 | 98,846,983.95 | - | 179,165,547.08 |
| 公告日期 | 2026-10-22 | 2026-08-06 | 2026-04-22 | 2026-04-22 |
| 审计意见(境内) | | | | 标准无保留意见 |